# US 2025/0375498 A1 · Neurotrimin function inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375498 A1
- Document ID: US20250375498A1
- Status: Published application
- Kind: A1
- Application number: 18/993,828
- Filed: 2023-07-18
- Published: 2025-12-11
- Earliest claimed: 2022-07-28
- Assignees: The University of Tokyo
- Applicants: The University of Tokyo
- Inventors: Tetsu AKIYAMA; Yuki KAMOSHIDA; Tomoatsu HAYASHI; Yusuke YAMAZUMI; Takeaki ODA; Mima SHIKANAI
- Web page: https://patentgrep.com/patent/US20250375498A1

## CPC

- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/10: for accommodation disorders, e.g. myopia
- A61P 27/12: for cataracts
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 5/0819: {with the first amino acid being acidic}
- C07K 5/0821: {with the first amino acid being heterocyclic, e.g. His, Pro, Trp}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/502: {for testing non-proliferative effects}
- G01N 33/5023: {on expression patterns}
- G01N 33/5041: {involving analysis of members of signalling pathways}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- G01N 2500/10: involving cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

It is an object of the present invention to provide a cellular senescence-suppressing agent, and a preventive or therapeutic agent for diseases, etc. provided by cellular senescence. More specifically, the present invention relates to a cellular senescence-suppressing agent, comprising, as an active ingredient, an agent for inhibiting the function of NTM (Neurotrimin), and a medicament, etc., comprising the cellular senescence-suppressing agent. Moreover, the present invention relates to an antibody that suppresses senescence. Furthermore, the present invention relates to a method of screening for a substance that suppresses cellular senescence.

## Claims

### Claim 1

A cellular senescence-suppressing agent, comprising, as an active ingredient, an NTM (Neurotrimin) function inhibitor.

### Claim 2 (depends on 1)

The cellular senescence-suppressing agent according to claim 1, wherein the NTM function inhibitor is an antibody or an antigen-biding fragment thereof, a peptide aptamer, a specialty peptide, a nucleic acid or a low-molecular-weight compound.

### Claim 3 (depends on 2)

An agent capable of improving individual aging, comprising the cellular senescence-suppressing agent according to claim 2.

### Claim 4 (depends on 2)

An agent capable of improving obesity, comprising the cellular senescence-suppressing agent according to claim 2.

### Claim 5 (depends on 2)

A pharmaceutical composition capable of preventing or treating a disease provoked by cellular senescence, the pharmaceutical composition comprising the cellular senescence-suppressing agent according to claim 2.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the disease provoked by cellular senescence is at least one selected from the group consisting of cancer, diabetes, hypertension, dyslipidemia, arteriosclerosis, cerebral infarction, heart disease (myocardial infarction, cardiomyopathy and cardiac hypertrophy), chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease (cirrhosis, hepatitis and fatty liver), dementia (Alzheimer's disease), Parkinson's disease, frailty syndrome, sarcopenia, emaciation, osteoarthritis, spondylosis deformans, skin disease, senile alopecia, cataracts, dry eyes, glaucoma, age-related macular degeneration, presbyopia, other chronic inflammatory diseases, other metabolic diseases, and infectious diseases.

### Claim 7 (depends on 2)

A food and drink composition or a cosmetic composition, comprising the cellular senescence-suppressing agent according to claim 2.

### Claim 8 (depends on 7)

The food and drink composition or the cosmetic composition according to claim 7, wherein the food or drink composition or the cosmetic composition is configured to contribute to anti-aging, dieting, or lowering blood sugar levels.

### Claim 9

An antibody or an antigen-binding fragment thereof, wherein the amino acid sequences of CDRs (complementarity determining regions) 1 to 3 satisfy any of the following (A), (B), (C), (D) or (E):
(A)
heavy chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 3,
heavy chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 4,
heavy chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 5,
light chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 6,
light chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 7, and
light chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 8;
(B)
heavy chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 9,
heavy chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 10,
heavy chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 11,
light chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 12,
light chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 13, and
light chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 14;
(C)
heavy chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 15,
heavy chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 16,
heavy chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 17,
light chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 18,
light chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 19, and
light chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 20;
(D)
heavy chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 21,
heavy chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 22,
heavy chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 23,
light chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 24,
light chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 25, and
light chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 26; or
(E)
heavy chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 27,
heavy chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 28,
heavy chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 29,
light chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 30,
light chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 31, and
light chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 32.

### Claim 10 (depends on 9)

An antibody that suppresses or inhibits the function of NTM, wherein the antibody competitively inhibits binding between the antibody or antigen-binding fragment thereof according to claim 9 and NTM.

### Claim 11 (depends on 9)

The antibody or antigen-binding fragment according to claim 9, wherein the antibody or antigen-binding fragment thereof is Fab, Fab′, F(ab′)2, Fv, a single-chain antibody, scFv, an scFv dimer, or dsFv.

### Claim 12

A method of screening for a substance that suppresses cellular senescence, comprising the following (a) and (b):
(a) allowing NTM and a candidate substance to come into contact with cells; and
(b) evaluating the degree of cellular senescence of the cells with which the NTM and the candidate substance are allowed to come into contact.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the degree of cellular senescence is evaluated using, as an indicator, the expression level of a cellular senescence marker or the expression level of an SASP (senescence-associated secretory phenotype)-related factor.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the cellular senescence marker is p16, p15, or p21.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the SASP-related factor is an IL-6 or IL-8 gene.

### Claim 16 (depends on 2)

The cellular senescence-suppressing agent according to claim 2,
wherein the NTM function inhibitor is the antibody or antigen-binding fragment thereof, and
wherein the amino acid sequences of CDRs 1 to 3 of the antibody or antigen-binding fragment thereof satisfy any of the following (A), (B), (C), (D) or (E):
(A)
heavy chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 3,
heavy chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 4,
heavy chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 5,
light chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 6,
light chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 7, and
light chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 8;
(B)
heavy chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 9,
heavy chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 10,
heavy chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 11,
light chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 12,
light chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 13, and
light chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 14;
(C)
heavy chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 15,
heavy chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 16,
heavy chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 17,
light chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 18,
light chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 19, and
light chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 20;
(D)
heavy chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 21,
heavy chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 22,
heavy chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 23,
light chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 24,
light chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 25, and
light chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 26; or
(E)
heavy chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 27,
heavy chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 28,
heavy chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 29,
light chain CDR1 comprising the amino acid sequence as set forth in SEQ ID No: 30,
light chain CDR2 comprising the amino acid sequence as set forth in SEQ ID No: 31, and
light chain CDR3 comprising the amino acid sequence as set forth in SEQ ID No: 32.

### Claim 17 (depends on 2)

A method of improving individual aging, comprising administering the cellular senescence-suppressing agent according to claim 2 to a subject in need thereof.

### Claim 18 (depends on 2)

A method of improving obesity, comprising administering the cellular senescence-suppressing agent according to claim 2 to a subject in need thereof.

### Claim 19 (depends on 2)

A method of preventing or treating a disease provoked by cellular senescence, comprising administering the cellular senescence-suppressing agent according to claim 2 to a subject in need thereof.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the disease provoked by cellular senescence is at least one selected from the group consisting of cancer, diabetes, hypertension, dyslipidemia, arteriosclerosis, cerebral infarction, heart disease (myocardial infarction, cardiomyopathy and cardiac hypertrophy), chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease (cirrhosis, hepatitis and fatty liver), dementia (Alzheimer's disease), Parkinson's disease, frailty syndrome, sarcopenia, emaciation, osteoarthritis, spondylosis deformans, skin disease, senile alopecia, cataracts, dry eyes, glaucoma, age-related macular degeneration, presbyopia, other chronic inflammatory diseases, other metabolic diseases and infectious diseases.
